New York-based Regeneron has announced that it will allow one of its key partnerships with the French drug maker Sanofi to terminate at the end of the year without an extension. The companies’ Antibody Discovery Agreement was responsible for the discovery and development of such drugs as alirocumab (Praluent), dupilumab (Dupixent), and sarilumab (Kevzara).
New York-based Regeneron has announced that it will allow one of its key partnerships with the French drug maker Sanofi to terminate at the end of the year without an extension.
The companies’ Antibody Discovery Agreement was responsible for the discovery and development of such drugs as alirocumab (Praluent), dupilumab (Dupixent), and sarilumab (Kevzara), as well as the proposed monoclonal antibodies REGN2810, REGN3500, and REGN3767.
Sanofi and Regneron will continue to co-develop REGN2810, a programmed death-1 antibody, and REGN3767, a lymphocyte activation gene-3 antibody (both for the treatment of cancer) under their immuno-oncology collaboration. That separate agreement will remain in force through at least 2020, and FieceBiotech reports that a Sanofi representative has confirmed its continued involvement with Regeneron on both ongoing and new initiatives under that agreement. The joint development and eventual prospective commercialization of REGN3500, an IL-33 antibody for the treatment of inflammatory diseases, will continue as part of their Antibody License and Collaboration Agreement.
Regeneron also reports that it has entered into clinical study agreements for RGN2810 with Inovo Pharmaceuticals and SillaJen to evaluate the proposed antibody for use in combination with their own product candidates. Regeneron indicated that it retained the right to develop products initiated under the Antibody Discovery Agreement, either alone or in conjunction with other companies, after the Sanofi agreement lapses.
Regeneron entered into its initial partnership with Sanofi in 2007, with a scheduled expiration of the Antibody Discovery Agreement in 2012. However, the companies chose to renew that partnership in 2009, with a higher level of funding dedicated to the projects covered by the agreement. Under the 2009 renewal, Sanofi was responsible for providing up to $160 million in funding annually for Regeneron’s antibody research. According to Regeneron, the $130 million in funding provided by Sanofi for the 2017 fiscal year will be exhausted by the end of the third quarter.
The termination of the Antibody Discovery Agreement comes after impressive successes for the partnership; the companies’ sarilumab gained regulatory approval in both the United States and the European Union this year, and the drug outperformed AbbVie’s blockbuster adalimumab (Humira) as monotherapy for the treatment of rheumatoid arthritis in a phase 3 study. Dupilumab, which is currently being studied in asthma, pediatric atopic dermatitis, and other indications, realized global sales of $29 million in the second quarter of 2017. Alirocumab, used for the treatment of elevated low-density lipoprotein cholesterol, saw $46 million in global sales (compared with $24 million in the same quarter in 2016).
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.